
Conference Coverage
Latest Content

Boston Panel Confronts Access and Coordination Gaps in Obesity Care

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

LGBTQ+ Medical Students Favor States With Protections

Longer-Acting DME Drugs Ease Burden, Not Vision: John Kitchens, MD

Shorts










Center on Health Equity & Access
All News

Chronic skin disorders are psychologically impacting children and adolescents, reinforcing the need for routine mental health screening.

Brittany G. Craiglow, MD, FAAD, discusses the psychiatric and psychosocial toll of alopecia in children and adolescents, and its impact on treatment initiation.

Experts discussed innovations in oncology care, treatment access, pharmacy workflows, and patient outcomes.

Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.

The new MonumenTAL-6 combination data appear to exceed MajesTEC-9 numbers.

FAQs address Cyclospora recovery, high-risk populations, antibiotic use, C. difficile risk, and CDC/FDA outbreak response.

The Pharmacy Compounding Advisory Committee narrowly recommended BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon for the 503A Bulks List.

People with HIV born after 1980 had an 81% lower risk of hepatitis B coinfection than earlier cohorts, highlighting the lasting impact of childhood vaccination.

Black, Latino boys' stigma persists; AHRQ halts 100+ grants; Delgocitinib succeeds in teens; Medicaid frail rule stands; BIPOC eating care improves.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.
























